Braidwell’s Verve Therapeutics VERV Stock Holding History

Braidwell’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-623,980	Closed	-$3.02M	–	92
2024 Q3	$3.02M	Buy	+623,980	New	+$3.62M	0.09%	76

Other funds holding VERV

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Braidwell's VERV Position: Q4 2024 in Review

Braidwell sold out of Verve Therapeutics (VERV) in Q4 2024, closing a stake of 623,980 shares — an estimated $3.02M sold.

Braidwell first reported a position in VERV in Q3 2024 and held it in 1 quarter. The position peaked at $3.02M in Q3 2024. 166 funds tracked by Wall St. Rank hold VERV as of Q4 2024.

Braidwell reported no remaining Verve Therapeutics position as of Q4 2024 after selling out during the quarter.
Braidwell sold 623,980 Verve Therapeutics shares in Q4 2024, an estimated $3.02M.
Braidwell first reported a position in Verve Therapeutics in Q3 2024 and held it in 1 quarter.
Braidwell's Verve Therapeutics position peaked at $3.02M in Q3 2024.
166 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2024.

Based on Braidwell's 13F filing for Q4 2024, filed 14 Feb 2025.